Skip to main content

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
Français FR
Home Home

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process
Français FR

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
  • Home /
  • Listing 3 - Actual negotiations

Listing 3 - Actual negotiations

Search by drug, manufacturer, or indication

Displaying 231 - 240 of 1165

Bylvay (odevixibat)

Status:

Concluded with an LOI

Manufacturer:

Medison Pharma Canada Inc.

Indication:

Pruritus in patients aged 6 months or older with progressive familial intrahepatic cholestasis (PFIC).

Last updated August 6, 2025

Vyloy (zolbetuximab)

Status:

Concluded with an LOI

Manufacturer:

Astellas Pharma Inc.

Indication:

In combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive

Last updated July 31, 2025

Casgevy (exagamglogene autotemcel)

Status:

Active negotiation

Manufacturer:

Vertex Pharmaceuticals (Canada) Incorporated

Indication:

Sickle cell disease

Last updated July 29, 2025

Casgevy (exagamglogene autotemcel)

Status:

Active negotiation

Manufacturer:

Vertex Pharmaceuticals (Canada) Incorporated

Indication:

Transfusion-dependent ?-thalassemia

Last updated July 29, 2025

Keytruda (pembrolizumab)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

In combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).

Last updated July 24, 2025

Crysvita (burosumab)

Status:

Concluded with an LOI

Manufacturer:

Kyowa Kirin Canada, Inc.

Indication:

X-Linked Hypophosphatemia

Last updated July 21, 2025

Omlyclo (omalizumab)

Status:

Concluded with an LOI

Manufacturer:

Celltrion Healthcare Canada Ltd.

Indication:

Multiple Indications

Last updated July 14, 2025

Evkeeza (evinacumab)

Status:

Concluded with an LOI

Manufacturer:

Ultragenyx Pharmaceutical Inc.

Indication:

Homozygous Familial Hypercholesterolemia

Last updated July 8, 2025

Winlevi (clascoterone)

Status:

Negotiations were not pursued

Manufacturer:

Sun Pharma Canada Inc.

Indication:

Acne Vulgaris

Last updated July 4, 2025

Ultomiris (ravulizumab)

Status:

Concluded with an LOI

Manufacturer:

Alexion Pharma GmbH

Indication:

Generalized myasthenia gravis (gMG)

Last updated July 3, 2025

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 22
  • Page 23
  • Current page 24
  • Page 25
  • Page 26
  • …
  • Next page Next ›
  • Last page Last »

Page updated: February 12, 2026

Our team is located across the country, on the ancestral and unceded territories of Canada’s Indigenous Peoples. We recognize their inherent and treaty rights, and we’re grateful to stand, live, and work on these lands.

pan-Canadian Pharmaceutical Association

General inquiries: Email us

Footer Navigation

  • Inside the pCPA
    • Who we are
    • What we do
    • Our vision and strategy
    • Governance
    • Members
  • Insights and updates
    • Our role
    • Drugs we negotiate
    • Performance dashboard
    • News
    • Glossary
  • Negotiations
    • Recent negotiation activity
    • Standard negotiations
    • Expedited pathways
    • Biosimilar drugs
    • Brand-name drugs
    • Generic Drugs

Footer secondary

  • Browse negotiations
  • Careers
  • Contact us
  • News

Copyright © 2026 pan-Canadian Pharmaceutical Alliance. All rights reserved.

Footer Utility

  • Privacy Policy
  • Terms of use